Stock AnalizCencora, Inc. COR
Other Pharmaceuticals · data as of November 13, 2026
Cencora, Inc. (COR) is a healthcare company listed in the US with a market value of about $68.5B. In the twelve months to September 30, 2026 it had revenue of $337.4B and net income of $3.5B, a net margin of 1.0%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is shareholder returns (5/5); the weakest is future growth (2/5).
Key numbers: a P/E of 20.1, a price to free cash flow of 17.7, 5-year revenue growth of 11% a year, a 5-year average ROIC of 24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 14% below the current price.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- More cash than debt, or low debt to equity
- Debt below 3 years of free cash flow
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $337.4B | $321.3B | $294.0B | $262.2B | $238.6B | $214.0B | $189.9B | $179.6B | $167.9B | $153.1B | $146.8B |
| Net income | $3.5B | $1.6B | $1.5B | $1.7B | $1.7B | $1.5B | -$3.4B | $855M | $1.7B | $364M | $1.4B |
| Free cash flow | $3.9B | $3.2B | $3.0B | $3.5B | $2.2B | $2.2B | $1.8B | $2.0B | $1.1B | $1.0B | $2.7B |
| EPS (diluted) | $17.87 | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 | $-16.65 | $4.04 | $7.53 | $1.64 | $6.32 |
| Net margin | 1.0% | 0.5% | 0.5% | 0.7% | 0.7% | 0.7% | -1.8% | 0.5% | 1.0% | 0.2% | 1.0% |
| ROIC | — | 16.8% | 26.3% | 29.2% | 27.7% | 20.4% | -92.2% | 12.9% | 15.8% | 15.2% | 19.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $381.25, 6% above the current price; targets range from $330.00 to $413.00; the consensus rating is “Buy”; expected EPS is $19.62 for the fiscal year ending September 30, 2027.
Frequently asked questions
What is Cencora’s P/E ratio?
About 20.1, based on the last twelve months of diluted earnings per share (forward P/E about 17.4).
Is Cencora stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 14% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cencora pay a dividend?
Yes. The dividend yield is about 0.75%, and it has paid dividends for 10 years in our data.
Is Cencora a good stock to buy?
We do not give buy or sell advice. Cencora scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.